- Home
- CNTB vs YARW Comparison
CNTB vs YARW Comparison
Compare CNTB & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | YARW |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 154.5M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTB | YARW |
|---|---|---|
| Price | $0.90 | $19.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $5.88 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.6M | 95.5K |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | $11,291.47 | N/A |
| Revenue Next Year | $74.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $18.05 |
| 52 Week High | $3.82 | $44.28 |
Technical Indicators
Market Signals| Indicator | CNTB | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 39.65 |
| Support Level | $0.85 | $18.24 |
| Resistance Level | $2.74 | $32.89 |
| Average True Range (ATR) | 0.08 | 1.97 |
| MACD | 0.03 | 0.26 |
| Stochastic Oscillator | 3.46 | 32.07 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.